Analysis Note

ControlPositive in RD cells, glioma cells, fibroblasts (SV-80), and MDCK cell line

Application

Western blot
Immunohistochemistry: 1:100; Frozen and paraffin-embedded tissue sections with a minimum of a one hour incubation (longer for paraffin); protease pretreatment is recommended for paraffin-embedded sections.
Immunofluorescence
ELISA

Optimal working dilutions must be determined by the end user.

Research Sub CategoryCytoskeleton

This Anti-Vimentin Antibody, clone VIM 3B4 is validated for use in ELISA, IF, IH(P), WB for the detection of Vimentin.

Research CategoryCell Structure

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Immunogen

Vimentin purified from bovine lens

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Protein A purified

Protein A Purified immunoglobulin presented as lyophilized material. Reconstitute with 1ml distilled water. Final solution is PBS, pH 7.4, containing 0.5% BSA and 0.09% sodium azide.

Format: Purified

Specificity

Highly specific for the intermediate filament protein vimentin which is present in all cells of mesenchymal origin. This antibody is positive with cells of mesenchymal derivation, including endothelial cells and certain smooth muscle cells of the vascular tract, fibroblasts, connective tissue, all types of blood cells, including thymocytes, interstitial and testicular Sertoli cells, ovarian follicle cells. It can also be used to detect coexpression of vimentin in combination with other intermediate filament proteins. VIM 3B4 has turned out to be the most avid monoclonal antibody to vimentin. Tumors specifically detected: sarcoma (including myosarcoma), lymphoma, melanoma. The binding region of monoclonal antibody VIM3B4 has been characterized by Bohn et al. (1992). According to these authors, the epitope has been localized on the alpha-helical part of vimentin (rod domain coil 2). Due to an aa substitution at position of aa 353 in murine vimentin (that could explain for the weak cross-reaction of the antibody with murine vimentin) they were able to narrow down the binding region around position 353. These findings were confirmed by truncation mutagenesis experiments using human vimentin (Rogers et al., 1995). Polypeptide reacting: MW 57 kDa intermediate filament protein (vimentin) of mesenchymal cells.

Storage and Stability

Maintain at 2–8°C for up to 12 months from date of receipt.

Target description

57 kDa